Promising Results With Trastuzumab Deruxtecan in Early HER2+ Breast Cancer

Leggi l'articolo originale


Researchers tested a novel antibody-drug conjugate known as trastuzumab deruxtecan in an expansion cohort of a phase I study of patients with advanced HER2+ breast cancer previously treated with trastuzumab emtansine.

Lascia un commento